Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 429
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Article in Russian | MEDLINE | ID: mdl-37966440

ABSTRACT

Bacosides are the main biologically active components derived from the plant bacopa monnieri (Bacopa monnieri (L.) Wettst.), which has been used as a nootropic in Indian medicine for many centuries. In recent years, these compounds have attracted attention because of their wide range of neurobiological effects. The neuroprotective effects of bacosides on brain neurons under the influence of various damaging factors (neurotoxins, oxidative stress, beta-amyloid deposition, cigarette smoke, etc.) have been established. It was shown that these substances reduce the levels of inflammatory cytokines and inhibit the processes of demyelination of neurons. The anticonvulsant effect of bacosides has been established. These compounds also improve cognitive functions, including memory and learning abilities. The effects associated with the influence on the dopaminergic and serotonergic systems of the striatum are of interest for the therapy of morphine addiction. The theoretical justifications for the future use of bacosides as a multipurpose means of complex therapy of individual diseases in neurological and psychiatric practice are presented.


Subject(s)
Anticonvulsants , Cognition , Saponins , Triterpenes , Humans , Brain , Corpus Striatum , Triterpenes/pharmacology , Saponins/pharmacology , Nootropic Agents/pharmacology
2.
Cent Nerv Syst Agents Med Chem ; 23(2): 126-136, 2023.
Article in English | MEDLINE | ID: mdl-37608652

ABSTRACT

BACKGROUND: The primary phytoconstituents reported to have neuroprotective effects are flavonoids and phenolic compounds. Aerva persica roots are reported to be rich in flavonoids and phenolic compounds. Therefore, this study aimed to explore the nootropic potential of Aerva persica roots. OBJECTIVE: The objective of this study was to evaluate the nootropic potential of Aerva persica roots against D-galactose-induced memory impairment. METHODS: In this study, the roots of Aerva persica were extracted with 70% ethanol. The obtained extract was evaluated for total phenolic content using the Folin-Ciocalteu method and total flavonoid content using the aluminium chloride colorimetric assay. Afterward, the acute oral toxicity of the extract was determined following the Organisation for Economic Co-operation and Development (OECD) guideline 423. Additionally, two doses of Aerva persica (100 and 200 mg/kg body weight (BW)) were evaluated for their nootropic potential against D-galactose-induced memory impairment. The nootropic potential of the crude extract was assessed through a behavioural study and brain neurochemical analysis. Behavioural studies involved the evaluation of spatial reference- working memory using the radial arm maze test and the Y-maze test. Neurochemical analysis was performed to determine the brain's acetylcholine, acetylcholinesterase, glutathione (GSH), and malondialdehyde (MDA) levels. RESULTS: The total phenolic content and total flavonoid content were found to be 179.14 ± 2.08 µg GAE/mg and 273.72 ± 3.94 µg QE/mg, respectively. The Aerva persica extract was found to be safe up to 2000 mg/kg BW. Following the safety assessment, the experimental mice received various treatments for 14 days. The behavioural analysis using the radial maze test showed that the extract at both doses significantly improved spatial reference-working memory and reduced the number of total errors compared to disease control groups. Similarly, in the Y-maze test, both doses significantly increased the alteration percentage and the percentage of novel arm entry (both indicative of intact spatial memory) compared to disease control. In neurochemical analysis, Aerva persica at 200 mg/kg significantly normalised the acetylcholine level (p<0.0001) and GSH level (p<0.01) compared to disease control. However, the same effect was not observed with Aerva persica at 100 mg/kg. Additionally, Aerva persica at 200mg/kg BW significantly decreased the acetylcholinesterase level (p<0.0001) and decreased the brain's MDA level (p<0.01) compared to the disease control, whereas the effect of Aerva persica at 100 mg/kg BW in reducing acetylcholinesterase was non-significant. CONCLUSION: Based on the results, it can be concluded that the nootropic potential of Aerva persica was comparable to that of the standard drug, Donepezil, and the effect might be attributed to the higher content of flavonoids and phenolic compounds.


Subject(s)
Amaranthaceae , Nootropic Agents , Mice , Animals , Nootropic Agents/pharmacology , Galactose/toxicity , Acetylcholinesterase , Acetylcholine/adverse effects , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Glutathione/adverse effects , Ethanol , Flavonoids/pharmacology , Flavonoids/therapeutic use , Maze Learning
3.
J Integr Neurosci ; 22(3): 76, 2023 May 16.
Article in English | MEDLINE | ID: mdl-37258429

ABSTRACT

PURPOSE: Opioid use disorder is a significant global problem. Chronic heroin use is associated with impairment of cognitive function and conscious control ability. The cholinergic system can be disrupted following heroin administration, indicating that activation of the cholinergic system may prevent chronic heroin misuse. Donepezil as an inhibitor of cholinesterase has been reported to clinically improve cognition and attention. In this study, the inhibition of heroin self-administration and heroin-seeking behaviours by donepezil were evaluated in rats. METHODS: Rats were trained to self-administer heroin every four hours for 14 consecutive days under a fixed ratio 1 (FR1) reinforcement schedule, then underwent withdrawal for two weeks. A progressive ratio schedule was then used to evaluate the relative motivational value of heroin reinforcement. After withdrawal, a conditioned cue was introduced for the reinstatement of heroin-seeking behaviour. Donepezil (0.3-3 mg/kg, i.p.) was used during both the FR1 heroin self-administration and progressive ratio schedules. Immunohistochemistry was used to investigate the mechanism of action of donepezil in the rat brain. RESULTS: Pre-treatment with high dose donepezil (3 mg/kg) but not low doses (0.3-1 mg/kg) significantly inhibited heroin self-administration under the FR1 schedule. Donepezil decreased motivation values under the progressive ratio schedule in a dose-dependent manner. All doses of donepezil (1-3 mg/kg) decreased the reinstatement of heroin seeking induced by cues. Correlation analysis indicated that the inhibition of donepezil on heroin-seeking behaviour was positively correlated with an increased expression of dopamine receptor 1 (D1R) and dopamine receptor 2 (D2R) in the nucleus accumbens (NAc) and increased expression of choline acetyltransferase (ChAT) in the ventral tegmental area (VTA). CONCLUSIONS: The present study demonstrated that donepezil could inhibit heroin intake and heroin-seeking behaviour. Further, donepezil could regulate dopamine receptors in the NAc via an increase of acetylcholine. These results suggested that donepezil could be developed as a potential approach for the treatment of heroin misuse.


Subject(s)
Heroin Dependence , Nootropic Agents , Rats , Animals , Heroin/pharmacology , Heroin/therapeutic use , Donepezil/pharmacology , Cues , Nootropic Agents/pharmacology , Conditioning, Operant , Heroin Dependence/drug therapy , Heroin Dependence/psychology , Rats, Sprague-Dawley , Receptors, Dopamine , Cholinergic Agents/therapeutic use , Extinction, Psychological
4.
Crit Rev Food Sci Nutr ; 63(22): 5521-5545, 2023.
Article in English | MEDLINE | ID: mdl-34978226

ABSTRACT

Substances with modulatory capabilities on certain aspects of human cognition have been revered as nootropics from the dawn of time. The plant kingdom provides most of the currently available nootropics of natural origin. Here, in this systematic review, we aim to provide state-of-the-art information regarding proven and unproven effects of plant-derived nootropics (PDNs) on human cognition in conditions of health and disease. Six independent searches, one for each neurocognitive domain (NCD), were performed in parallel using three independent scientific library databases: PubMed, Cochrane and Scopus. Only scientific studies and systematic reviews with humans published between January 2000 and November 2021 were reviewed, and 256 papers were included. Ginkgo biloba was the most relevant nootropic regarding perceptual and motor functions. Bacopa monnieri improves language, learning and memory. Withania somnifera (Ashwagandha) modulates anxiety and social-related cognitions. Caffeine enhances attention and executive functions. Together, the results from the compiled studies highlight the nootropic effects and the inconsistencies regarding PDNs that require further research.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2021.2021137.


Subject(s)
Nootropic Agents , Humans , Nootropic Agents/pharmacology , Plant Extracts/pharmacology , Cognition , Phytotherapy
5.
J Ethnopharmacol ; 300: 115671, 2023 Jan 10.
Article in English | MEDLINE | ID: mdl-36055476

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Kalyanaka ghrita (KG) is an Ayurvedic formulation traditionally used in the treatment of Daurbalya (debility) and Smritidaurbalya (impairment of intellectual activities). Clinical studies have reported the effect of KG in the treatment of Manasmandata or Buddhimandyata which is associated with impaired learning, social adjustment and maturation. AIM OF THE STUDY: The present study aims to standardization of KG and validation of its use in experimental models of neurodegeneration. MATERIALS AND METHODS: KG was Standardized for biomarkers curcumin, gallic acid, tannic acid, chebulagic acid, and berberine. In male wistar rats, neurodegeneration was induced by administration of intracerebroventricular Amyloid ß (Aß1-42). The effect of KG (oral and intranasal treatment) was evaluated through behavioral parameters such as Morris water maze, social recognition test, novel object recognition, locomotor activity, and molecular parameters, brain acetylcholinesterase, brain-derived neurotrophic factor (BDNF), inflammatory cytokines, oxidative stress markers, and antioxidants. Brain histopathology was performed for studying the architecture of the brain and plaque formation. RESULTS AND DISCUSSION: A novel HPLC method has been developed for the standardization of KG. Treatment with KG significantly improved cognition and memory and increased brain BDNF and antioxidant status in Aß1-42 induced rats. It also reduced brain acetylcholinesterase, oxidative stress, and inflammatory cytokines and prevented neuronal damage. There were more marked effects with intra-nasal administration compared to oral treatment. CONCLUSION: The findings suggest that KG has neuroprotective potential and along with its nootropic property could be a promising therapy for neurodegenerative diseases like Alzheimer's disease.


Subject(s)
Alzheimer Disease , Berberine , Curcumin , Neuroprotective Agents , Nootropic Agents , Acetylcholinesterase , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/toxicity , Animals , Antioxidants , Berberine/pharmacology , Brain-Derived Neurotrophic Factor , Curcumin/pharmacology , Cytokines/pharmacology , Disease Models, Animal , Male , Maze Learning , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Nootropic Agents/pharmacology , Rats , Rats, Wistar , Tannins/pharmacology
6.
Curr Med Sci ; 42(1): 39-47, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35122611

ABSTRACT

OBJECTIVE: Angelica (A.) sinensis is used as a traditional medical herb for the treatment of neurodegeneration, aging, and inflammation in Asia. A. sinensis optimal formula (AOF) is the best combination in A. sinensis that has been screened to rescue the cognitive ability in ß-amyloid peptide (Aß25-35)-treated Alzheimer's disease (AD) rats. The objective of this study was to investigate the effect of AOF on the learning and memory of AD rats as well as to explore the underlying mechanisms. METHODS: Male Wistar rats were infused with Aß25-35 for AD model induction or saline (negative control). Five groups of AD rats were fed on AOF at 20, 40, or 80 mL/kg every day, donepezil at 0.9 mg/kg every day (positive control), or an equal volume of water (AD model) intragastrically once a day for 4 weeks, while the negative control rats were fed on water. The Morris water maze test was used to evaluate the cognitive function of the rats. The Aß accumulation, cholinergic levels, and antioxidative ability were detected by ELISA. Additionally, the candidate mechanism was determined by gene sequencing and quantitative real-time polymerase chain reaction. RESULTS: The results showed that AOF administration significantly ameliorated Aß25-35-induced memory impairment. AOF decreased the levels of amyloid-ß precursor protein and Aß in the hippocampus, rescued the cholinergic levels, increased the activity of superoxide dismutase, and decreased the malondialdehyde level. In addition, AOF inhibited the expression of IL1b, Mpo, and Prkcg in the hippocampus. CONCLUSION: These experimental findings illustrate that AOF prevents the decrease in cognitive function and Aß deposits in Aß25-35-treated rats via modulating neuroinflammation and oxidative stress, thus highlighting a potential therapeutic avenue to promote the co-administration of formulas that act on different nodes to maximize beneficial effects and minimize negative side effects.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/pharmacology , Angelica sinensis , Memory Disorders/drug therapy , Neuroinflammatory Diseases/drug therapy , Nootropic Agents/pharmacology , Oxidative Stress/drug effects , Plant Preparations/pharmacology , Alzheimer Disease/chemically induced , Alzheimer Disease/immunology , Alzheimer Disease/metabolism , Animals , Disease Models, Animal , Male , Memory Disorders/chemically induced , Memory Disorders/immunology , Memory Disorders/metabolism , Neuroinflammatory Diseases/chemically induced , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/metabolism , Nootropic Agents/administration & dosage , Plant Preparations/administration & dosage , Rats , Rats, Wistar
7.
Food Funct ; 12(21): 10690-10699, 2021 Nov 01.
Article in English | MEDLINE | ID: mdl-34605514

ABSTRACT

Memory decline occurs due to various factors, including stress, depression, and aging, and lowers the quality of life. Several nutritional supplements and probiotics have been used to enhance memory function, and efforts have been made to develop mixed supplements with maximized efficacy. In this study, we aimed to examine whether a novel formulation composed of Cuscuta seeds and Lactobacillus paracasei NK112, CCL01, enhances memory function and induces neurogenesis via nerve growth factor (NGF) induction. Firstly, we orally administered CCL01 to normal mice and assessed their memory function 4 weeks after the first administration by performing a step-through passive avoidance test. We found that CCL01 at 100 mg kg-1 treatment enhanced the fear-based memory function. By analyzing the expression of Ki-67 and doublecortin, which are the markers of proliferating cells and immature neurons, respectively, we observed that CCL01 induced neuronal proliferation and differentiation in the hippocampus of the mice. Additionally, we found that the expression of synaptic markers increased in the hippocampus of CCL01-treated mice. We measured the NGF expression in the supernatant of C6 cells after CCL01 treatment and found that CCL01 increased NGF release. Furthermore, treatment of CCL01-conditioned glial media on N2a cells increased neuronal differentiation via the TrkA/ERK/CREB signaling pathway and neurotrophic factor expression. Moreover, when CCL01 was administered and scopolamine was injected, CCL01 ameliorated memory decline. These results suggest that CCL01 is an effective enhancer of memory function and can be applied to various age groups requiring memory improvement.


Subject(s)
Cuscuta/chemistry , Lacticaseibacillus paracasei , Memory/drug effects , Nerve Growth Factor/drug effects , Neurogenesis/drug effects , Seeds/chemistry , Animals , Cell Line, Tumor , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Extracellular Signal-Regulated MAP Kinases/genetics , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation/drug effects , Glioma/drug therapy , Male , Mice , Mice, Inbred ICR , Neuroblastoma/drug therapy , Neurogenesis/physiology , Neurons/drug effects , Nootropic Agents/pharmacology , Phytotherapy , Piracetam/pharmacology , Rats , Receptor, trkA/genetics , Receptor, trkA/metabolism , Synaptophysin/genetics , Synaptophysin/metabolism
8.
J Neurophysiol ; 126(5): 1622-1634, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34495785

ABSTRACT

Choline is an essential nutrient under evaluation as a cognitive enhancing treatment for fetal alcohol spectrum disorders (FASD) in clinical trials. As a result, there is increased pressure to identify therapeutic mechanism(s) of action. Choline is not only a precursor for several essential cell membrane components and signaling molecules but also has the potential to directly affect synaptic mechanisms that are believed important for cognitive processes. In the current work, we study how the direct application of choline can affect synaptic transmission in the dentate gyrus (DG) of hippocampal slices obtained from adolescent (postnatal days 21-28) Sprague-Dawley rats (Rattus norvegicus). The acute administration of choline chloride (2 mM) reliably induced a long-term depression (LTD) of field excitatory postsynaptic potentials (fEPSPs) in the DG in vitro. The depression required the involvement of M1 receptors, and the magnitude of the effect was similar in slices obtained from male and female animals. To further study the impact of choline in an animal model of FASD, we examined offspring from dams fed an ethanol-containing diet (35.5% ethanol-derived calories) throughout gestation. In slices from the adolescent animals that experienced prenatal ethanol exposure (PNEE), we found that the choline induced an LTD that uniquely involved the activation of N-methyl-d-aspartate (NMDA) and M1 receptors. This study provides a novel insight into how choline can modulate hippocampal transmission at the level of the synapse and that it can have unique effects following PNEE.NEW & NOTEWORTHY Choline supplementation is a nutraceutical therapy with significant potential for a variety of developmental disorders; however, the mechanisms involved in its therapeutic effects remain poorly understood. Our research shows that choline directly impacts synaptic communication in the brain, inducing a long-term depression of synaptic efficacy in brain slices. The depression is equivalent in male and female animals, involves M1 receptors in control animals, but uniquely involves NMDA receptors in a model of FASD.


Subject(s)
Central Nervous System Depressants/pharmacology , Choline/pharmacology , Dentate Gyrus/drug effects , Ethanol/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Fetal Alcohol Spectrum Disorders/physiopathology , Long-Term Synaptic Depression/drug effects , Nootropic Agents/pharmacology , Prenatal Exposure Delayed Effects/physiopathology , Receptor, Muscarinic M1/drug effects , Receptors, N-Methyl-D-Aspartate/drug effects , Synaptic Transmission/drug effects , Animals , Disease Models, Animal , Female , Male , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Rats , Rats, Sprague-Dawley
9.
Sci Rep ; 11(1): 17747, 2021 09 07.
Article in English | MEDLINE | ID: mdl-34493757

ABSTRACT

Deregulation of synaptic function and neurotransmission has been linked with the development of major depression disorder (MDD). Tianeptine (Tian) has been used as antidepressant with anxiolytic properties and recently as a nootropic to improve cognitive performance, but its mechanism of action is unknown. We conducted a proteomic study on the hippocampal synaptosomal fractions of adult male Wistar rats exposed to chronic social isolation (CSIS, 6 weeks), an animal model of depression and after chronic Tian treatment in controls (nootropic effect) and CSIS-exposed rats (lasting 3 weeks of 6-week CSIS) (therapeutic effect). Increased expression of Syn1 and Camk2-related neurotransmission, vesicle transport and energy processes in Tian-treated controls were found. CSIS led to upregulation of proteins associated with actin cytoskeleton, signaling transduction and glucose metabolism. In CSIS rats, Tian up-regulated proteins involved in mitochondrial energy production, mitochondrial transport and dynamics, antioxidative defense and glutamate clearance, while attenuating the CSIS-increased glycolytic pathway and cytoskeleton organization proteins expression and decreased the expression of proteins involved in V-ATPase and vesicle endocytosis. Our overall findings revealed that synaptic vesicle dynamics, specifically exocytosis, and mitochondria-related energy processes might be key biological pathways modulated by the effective nootropic and antidepressant treatment with Tian and be a potential target for therapeutic efficacy of the stress-related mood disorders.


Subject(s)
Antidepressive Agents/pharmacology , Depressive Disorder/drug therapy , Mitochondria/drug effects , Nootropic Agents/pharmacology , Proteome/drug effects , Social Isolation , Synaptic Vesicles/drug effects , Thiazepines/pharmacology , Animals , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Antidepressive Agents/therapeutic use , Depressive Disorder/physiopathology , Disease Models, Animal , Drug Evaluation, Preclinical , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/ultrastructure , Male , Mitochondria/physiology , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/genetics , Nootropic Agents/therapeutic use , Protein Interaction Mapping , Rats , Rats, Wistar , Signal Transduction/drug effects , Thiazepines/therapeutic use
10.
Nutrients ; 13(8)2021 Aug 23.
Article in English | MEDLINE | ID: mdl-34445062

ABSTRACT

Allium hookeri (AH) is a medicinal food that has been used in Southeast Asia for various physiological activities. The objective of this study was to investigate the activation of the cholinergic system and the anti-neuroinflammation effects of AH on scopolamine-induced memory impairment in mice. Scopolamine (1 mg/kg body weight, i.p.) impaired the performance of the mice on the Y-maze test, passive avoidance test, and water maze test. However, the number of error actions was reduced in the AH groups supplemented with leaf and root extracts from AH. AH treatment improved working memory and avoidance times against electronic shock, increased step-through latency, and reduced the time to reach the escape zone in the water maze test. AH significantly improved the cholinergic system by decreasing acetylcholinesterase activity, and increasing acetylcholine concentration. The serum inflammatory cytokines (IL-1ß, IL-6, and IFN-γ) increased by scopolamine treatment were regulated by the administration of AH extracts. Overexpression of NF-κB signaling and cytokines in liver tissue due to scopolamine were controlled by administration of AH extracts. AH also significantly decreased Aß and caspase-3 expression but increased NeuN and ChAT. The results suggest that AH extracts improve cognitive effects, and the root extracts are more effective in relieving the scopolamine-induced memory impairment. They have neuroprotective effects and reduce the development of neuroinflammation.


Subject(s)
Allium , Anti-Inflammatory Agents/pharmacology , Brain/drug effects , Cholinergic Neurons/drug effects , Cognition/drug effects , Cognitive Dysfunction/drug therapy , Cytokines/blood , Inflammation Mediators/blood , Memory Disorders/drug therapy , Memory/drug effects , Nootropic Agents/pharmacology , Plant Extracts/pharmacology , Acetylcholine/blood , Acetylcholinesterase/blood , Allium/chemistry , Animals , Behavior, Animal/drug effects , Brain/metabolism , Brain/pathology , Cholinergic Neurons/metabolism , Cholinergic Neurons/pathology , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/psychology , Disease Models, Animal , GPI-Linked Proteins/blood , Male , Maze Learning/drug effects , Memory Disorders/chemically induced , Memory Disorders/metabolism , Memory Disorders/psychology , Mice, Inbred C57BL , Plant Extracts/isolation & purification , Plant Leaves , Plant Roots , Scopolamine
11.
Int J Mol Sci ; 22(14)2021 Jul 08.
Article in English | MEDLINE | ID: mdl-34298986

ABSTRACT

Alzheimer's disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes-low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests-followed by validation in in vivo models.


Subject(s)
Alzheimer Disease/drug therapy , Monoterpenes/therapeutic use , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Phytotherapy , Acetylcholine/physiology , Acetylcholinesterase/chemistry , Alzheimer Disease/metabolism , Animals , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Apolipoproteins E/genetics , Apolipoproteins E/physiology , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Computer Simulation , Drug Evaluation, Preclinical , Encephalitis/complications , Encephalitis/metabolism , Humans , Iridoids/therapeutic use , Learning/drug effects , Memory/drug effects , Mice , Models, Molecular , Monoterpenes/pharmacology , Nerve Tissue Proteins/physiology , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Oxidative Stress/drug effects , Polyphenols/pharmacology , Polyphenols/therapeutic use , Protein Conformation , Rats , Sleep Initiation and Maintenance Disorders/drug therapy , Sleep Initiation and Maintenance Disorders/etiology
12.
Neurochem Int ; 149: 105124, 2021 10.
Article in English | MEDLINE | ID: mdl-34245808

ABSTRACT

Brain and neuronal circuits constitute the most complex organ networks in human body. They not only control and coordinate functions of all other organs, but also represent one of the most-affected systems with stress, lifestyle and age. With global increase in aging populations, these neuropathologies have emerged as major concern for maintaining quality of life. Recent era has witnessed a surge in nutritional remediation of brain dysfunctions primarily by "nutraceuticals" that refer to functional foods and supplements with pharmacological potential. Specific dietary patterns with a balanced intake of carbohydrates, fatty acids, vitamins and micronutrients have also been ascertained to promote brain health. Dietary herbs and their phytochemicals with wide range of biological and pharmacological activities and minimal adverse effects have gained remarkable attention as neuro-nutraceuticals. Neuro-nutraceutical potentials of herbs are often expressed as effects on cognitive response, circadian rhythm, neuromodulatory, antioxidant and anti-inflammatory activities that are mediated by effects on gene expression, epigenetics, protein synthesis along with their turnover and metabolic pathways. Epidemiological and experimental evidence have implicated enormous applications of herbal supplementation in neurodegenerative and psychiatric disorders. The present review highlights the identification, experimental evidence and applications of some herbs including Bacopa monniera, Withania somnifera, Curcuma longa, Helicteres angustifolia, Undaria pinnatifida, Haematococcus pluvialis, and Vitis vinifera, as neuro-nutraceuticals.


Subject(s)
Antioxidants/therapeutic use , Brain Diseases/drug therapy , Brain/drug effects , Dietary Supplements , Nootropic Agents/therapeutic use , Plant Preparations/therapeutic use , Animals , Antioxidants/isolation & purification , Antioxidants/pharmacology , Brain/metabolism , Brain Diseases/metabolism , Humans , Nootropic Agents/isolation & purification , Nootropic Agents/pharmacology , Phytochemicals/isolation & purification , Phytochemicals/pharmacology , Phytochemicals/therapeutic use , Plant Preparations/isolation & purification , Plant Preparations/pharmacology
13.
ScientificWorldJournal ; 2021: 6649574, 2021.
Article in English | MEDLINE | ID: mdl-33994883

ABSTRACT

Garugapinnata Roxb. (Burseraceae) is a medium-sized tree widely available all over the tropical regions of Asia. Bryophyllum pinnatum (Lam) Oken. (Crassulaceae) is an indigenous and exotic plant grown in tropical regions. Both plants have been used for their anti-inflammatory, antioxidant, anticancer, wound healing, antidiabetic activities, etc. This investigation was designed to explore the result shown by methanolic extract of Garuga pinnata bark and Bryophyllum pinnatum leaves, on cognitive power and retention of the memory in experimental mice along with quantification of phenolic compounds and DPPH radicals neutralizing capacity. The memory-enhancing activity was determined by the elevated plus-maze method in Scopolamine-induced amnesic mice, using Piracetam as allopathic and Shankhpushpi as ayurvedic standard drugs. Two doses (200 and 400 mg/kg p.o.) of both extracts were administered to mice up to 8 consecutive days; transfer latency of individual group was recorded after 45 minutes and memory of the experienced things was examined after 1 day. DPPH assay method and the Folin-Ciocalteu method were employed to determine antioxidant potency and total phenol amount, respectively. 400 mg/kg of the methanolic B. pinnatum bark extract significantly improved memory and learning of mice with transfer latency (TL) of 32.75 s, which is comparable to that of standard Piracetam (21.78 s) and Shankhpushpi (27.83 s). Greater phenolic content was quantified in B. pinnatum bark extract (156.80 ± 0.33 µg GAE/mg dry extract) as well as the antioxidant potency (69.77% of free radical inhibition at the 100 µg/mL concentration). Our study proclaimed the scientific evidence for the memory-boosting effect of both plants.


Subject(s)
Amnesia/drug therapy , Antioxidants/pharmacology , Burseraceae/chemistry , Kalanchoe/chemistry , Nootropic Agents/pharmacology , Phytochemicals/pharmacology , Amnesia/chemically induced , Amnesia/physiopathology , Animals , Antioxidants/isolation & purification , Biphenyl Compounds/antagonists & inhibitors , Cognition/drug effects , Cognition/physiology , Female , Male , Maze Learning/drug effects , Maze Learning/physiology , Memory/drug effects , Memory/physiology , Mice , Nootropic Agents/isolation & purification , Phenols/pharmacology , Phytochemicals/isolation & purification , Picrates/antagonists & inhibitors , Piracetam/pharmacology , Plant Bark/chemistry , Plant Extracts/chemistry , Plant Leaves/chemistry , Plant Preparations/pharmacology , Scopolamine/administration & dosage
14.
Mar Drugs ; 19(4)2021 Mar 27.
Article in English | MEDLINE | ID: mdl-33801706

ABSTRACT

We recently found that dietary supplementation with the seaweed Sargassum fusiforme, containing the preferential LXRß-agonist 24(S)-saringosterol, prevented memory decline and reduced amyloid-ß (Aß) deposition in an Alzheimer's disease (AD) mouse model without inducing hepatic steatosis. Here, we examined the effects of 24(S)-saringosterol as a food additive on cognition and neuropathology in AD mice. Six-month-old male APPswePS1ΔE9 mice and wildtype C57BL/6J littermates received 24(S)-saringosterol (0.5 mg/25 g body weight/day) (APPswePS1ΔE9 n = 20; C57BL/6J n = 19) or vehicle (APPswePS1ΔE9 n = 17; C57BL/6J n = 19) for 10 weeks. Cognition was assessed using object recognition and object location tasks. Sterols were analyzed by gas chromatography/mass spectrometry, Aß and inflammatory markers by immunohistochemistry, and gene expression by quantitative real-time PCR. Hepatic lipids were quantified after Oil-Red-O staining. Administration of 24(S)-saringosterol prevented cognitive decline in APPswePS1ΔE9 mice without affecting the Aß plaque load. Moreover, 24(S)-saringosterol prevented the increase in the inflammatory marker Iba1 in the cortex of APPswePS1ΔE9 mice (p < 0.001). Furthermore, 24(S)-saringosterol did not affect the expression of lipid metabolism-related LXR-response genes in the hippocampus nor the hepatic neutral lipid content. Thus, administration of 24(S)-saringosterol prevented cognitive decline in APPswePS1ΔE9 mice independent of effects on Aß load and without adverse effects on liver fat content. The anti-inflammatory effects of 24(S)-saringosterol may contribute to the prevention of cognitive decline.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Inflammatory Agents/pharmacology , Behavior, Animal/drug effects , Cerebral Cortex/drug effects , Cognition/drug effects , Nootropic Agents/pharmacology , Stigmasterol/analogs & derivatives , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Animals , Calcium-Binding Proteins/metabolism , Cell Line, Tumor , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Disease Models, Animal , Humans , Male , Mice, Inbred C57BL , Mice, Transgenic , Microfilament Proteins/metabolism , Microglia/drug effects , Microglia/metabolism , Recognition, Psychology/drug effects , Stigmasterol/pharmacology
15.
J Psychopharmacol ; 35(6): 621-630, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33645313

ABSTRACT

BACKGROUND: Mindfulness-meditation has a variety of benefits on well-being. However, individuals with primary attentional impairments (e.g. attention deficit disorder) or attentional symptoms secondary to anxiety, depression or addiction, may be less likely to benefit, and require additional mindfulness-augmenting strategies. AIMS: To determine whether a single dose of the cognitive enhancer, modafinil, acutely increases subjective and behavioural indices of mindfulness, and augments brief mindfulness training. METHODS: A randomised, double-blind, placebo-controlled, 2 (drug: placebo, modafinil) × 2 (strategy: mindfulness, relaxation control) experiment was conducted. Seventy-nine meditation-naïve participants were assigned to: placebo-relaxation, placebo-mindfulness, modafinil-relaxation or modafinil-mindfulness. Pre-drug, post-drug and post-strategy state mindfulness, affect and autonomic activity, along with post-strategy sustained attention and mind-wandering were assessed within a single lab session. After the session, participants were instructed to practice their assigned behavioural strategy daily for one week, with no further drug administration, after which, follow-up measures were taken. RESULTS: As predicted, modafinil acutely increased state mindfulness and improved sustained attention. Differential acute strategy effects were found following mindfulness on autonomic activity but not state mindfulness. There were no strategy or drug effects on mind-wandering. However, exploratory analyses indicated that participants receiving modafinil engaged in more strategy practice across strategy conditions during follow-up. CONCLUSIONS: Modafinil acutely mimicked the effects of brief mindfulness training on state mindfulness but did not enhance the effects of this training. Limitations of the current study, and recommendations for future research examining modafinil as an adjunct to mindfulness- (or relaxation-) based treatments are discussed.


Subject(s)
Meditation/methods , Mindfulness/methods , Modafinil/administration & dosage , Nootropic Agents/administration & dosage , Adolescent , Adult , Attention/drug effects , Attention Deficit Disorder with Hyperactivity/therapy , Combined Modality Therapy , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Modafinil/pharmacology , Nootropic Agents/pharmacology , Young Adult
16.
Neuropharmacology ; 187: 108489, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33561449

ABSTRACT

Rodent models have facilitated major discoveries in neurobiology, however, the low success rate of novel medications in clinical trials have led to questions about their translational value in neuropsychiatric drug development research. For age-related disorders of cognition such as Alzheimer' disease (AD) there is interest in moving beyond transgenic amyloid-ß and/or tau-expressing rodent models and focusing more on natural aging and dissociating "healthy" from "pathological" aging to identify new therapeutic targets and treatments. In complex disorders such as AD, it can also be argued that animals with closer neurobiology to humans (e.g., nonhuman primates) should be employed more often particularly in the later phases of drug development. The purpose of the work described here was to evaluate the cognitive capabilities of rhesus monkeys across a wide range of ages in different delayed response tasks, a computerized delayed match to sample (DMTS) task and a manual delayed match to position (DMTP) task. Based on specific performance criteria and comparisons to younger subjects, the older subjects were generally less proficient, however, some performed as well as young subjects, while other aged subjects were markedly impaired. Accordingly, the older subjects could be categorized as aged "cognitively-unimpaired" or aged "cognitively-impaired" with a third group (aged-other) falling in between. Finally, as a proof of principle, we demonstrated using the DMTP task that aged cognitively-impaired monkeys are sensitive to the pro-cognitive effects of a nicotinic acetylcholine receptor (nAChR) partial agonist, encenicline, suggesting that nAChR ligands remain viable as potential treatments for age-related disorders of cognition.


Subject(s)
Aging/psychology , Cognition/physiology , Cognitive Dysfunction/physiopathology , Memory, Short-Term/physiology , Animals , Cognition/drug effects , Drug Evaluation, Preclinical , Female , Macaca mulatta , Male , Memory, Short-Term/drug effects , Nootropic Agents/pharmacology , Quinuclidines/pharmacology , Thiophenes/pharmacology
17.
Sci Rep ; 11(1): 596, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33436817

ABSTRACT

Bacopa monnieri (Linn.) Wettst. has been used in traditional medicine as a drug to enhance and improve memory. In this regard, this study aims to provide B. monnieri's efficacy as a neuroprotective drug and as a nootropic against various neurological diseases. Literatures were collected, following Prisma guidelines, from databases, including Scopus, PubMed, Google Scholar, and Science Direct and were scrutinized using a quality scoring system. Means, standard deviations and 'n' numbers were extracted from the metrics and analyzed. Jamovi computer software for Mac was used to carry out the meta-analysis. The selected studies suggested that the plant extracts were able to show some improvements in healthy subjects which were determined in Auditory Verbal Learning Task, digit span-reverse test, inspection time task and working memory, even though it was not significant, as no two studies found statistically significant changes in the same two tests. B. monnieri was able to express modest improvements in subjects with memory loss, wherein only a few of the neuropsychological tests showed statistical significance. B. monnieri in a cocktail with other plant extracts were able to significantly reduce the effects of Alzheimer's disease, and depression which cannot be solely credited as the effect of B. monnieri. Although in one study B. monnieri was able to potentiate the beneficial effects of citalopram; on the whole, currently, there are only limited studies to establish the memory-enhancing and neuroprotective effects of B. monnieri. More studies have to be done in the future by comparing the effect with standard drugs, in order to establish these effects clinically in the plant and corroborate the preclinical data.


Subject(s)
Antidepressive Agents/pharmacology , Bacopa/chemistry , Cognitive Dysfunction/prevention & control , Depression/drug therapy , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Plant Extracts/pharmacology , Humans , Meta-Analysis as Topic
18.
Neurotox Res ; 39(3): 645-657, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33428179

ABSTRACT

At present, concerns are pointing to "tasteful" high-fat diets as a cause of conditioning physical-social states that through alterations of some key emotional- and nutritional-related limbic circuits such as hypothalamic and amygdalar areas lead to obesity states. Feeding and energetic homeostatic molecular mechanisms are part of a complex neuronal circuit accounting for this metabolic disorder. In an attempt to exclude conventional drugs for treating obesity, daidzein, a natural glycosidic isoflavone, which mimics estrogenic neuroprotective properties against increased body weight, is beginning to be preferred. In this study, evident anxiolytic-like behaviors were detected following treatment of high-fat diet hamsters with daidzein as shown by extremely evident (p < 0.001) exploration tendencies in novel object recognition test and a notably greater amount of time spent (p < 0.01) in open arms of elevated plus maze. Moreover, the isoflavone promoted a protective role against neurodegeneration processes as shown by few, if any, amino cupric silver granules in amygdalar, hypothalamic and hippocampal neuronal fields when compared with obese hamsters. Interestingly, elevated expression levels of the anorexic neuropeptide receptor neurotensin1 in the above limbic areas of obese hamsters were extremely reduced by daidzein, especially during recovery of cognitive events. Contextually, such effects were strongly paralleled by increased levels of the anti-neuroinflammatory cytokine, interleukin-10. Our results corroborate a neuroprotective ability of this natural glycosidic isoflavone, which through its interaction with the receptor neurotensin1 and interleukin-10 pathways is correlated not only to improved feeding states, and subsequently obesity conditions, but above all to cognitive performances.


Subject(s)
Brain/metabolism , Interleukin-10/biosynthesis , Isoflavones/pharmacology , Nootropic Agents/pharmacology , Obesity/metabolism , Receptors, Neurotensin/biosynthesis , Animals , Brain/drug effects , Cricetinae , Diet, High-Fat/adverse effects , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Gene Expression , Isoflavones/therapeutic use , Mesocricetus , Nootropic Agents/therapeutic use , Obesity/drug therapy , Obesity/psychology , Phytoestrogens/pharmacology , Phytoestrogens/therapeutic use
19.
Food Funct ; 12(1): 107-118, 2021 Jan 07.
Article in English | MEDLINE | ID: mdl-33331835

ABSTRACT

Blueberries (BB) contain an array of bioactive phenolic compounds that may play a protective role against various age-related diseases. Here we explored the metabolic fate of BB phenolics and their relationship to cognitive function after chronic (90 days) supplementation of freeze-dried BB (24 g d-1, equivalent to 1 cup of fresh BB) or control in a randomized, double-blind, parallel study with 38 healthy older adults (60-75 years). Blood samples were collected at fasting (t = 0 h) and 2 h after a breakfast meal on days 0 (no treatment), 45, and 90, and a battery of cognitive tests was also conducted on these days. Hippuric acid, phloroglucinaldehyde, syringic acid, ferulic acid-glucuronide, cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, malvidin-3-O-galactoside, malvidin-3-O-glucoside, peonidin-3-O-xyloside, peonidin glucuronide, and petunidin-3-O-glucoside concentrations were significantly altered after 90 days of BB consumption compared to control. Stepwise regression was used to assess the relationship between significantly altered concentrations of plasma phenolics and observed improvements in cognition. Among participants in the BB group, changes in switch errors on the task-switching test (TST) from day 0 to 90 were associated with changes in postprandial levels of plasma ferulic acid-glucuronide, syringic acid, and malvidin-3-galactoside (R2 = 0.521, p < 0.05). Changes in repetition errors on the California Verbal Learning Test (CVLT-II) from day 0 to 90 were associated with changes in postprandial levels of ferulic acid-glucuronide, syringic acid, and hippuric acid (R2 = 0.807, p < 0.001). These findings demonstrate that the addition of easily achievable quantities of BB to the diets of older adults significantly alters levels of circulating phenolic compounds which are related to improvements in cognition.


Subject(s)
Blueberry Plants , Cognition/drug effects , Dietary Supplements , Nootropic Agents/pharmacology , Phenols/pharmacology , Aged , Double-Blind Method , Female , Humans , Male , Middle Aged
20.
J Ethnopharmacol ; 269: 113711, 2021 Apr 06.
Article in English | MEDLINE | ID: mdl-33352242

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: EGb 761 is a standardized dry extract of Ginkgo biloba L. leaves traditionally used by Eastern Asia and has been associated with beneficial effects on neurodegeneration disorders, including Alzheimer's disease. AIM OF THE STUDY: Since beneficial interactions between EGb 761 and donepezil have been observed in previous clinical studies, the current study was proposed aiming to further explore related mechanisms from both pharmacokinetics and pharmacodynamics aspects. MATERIALS AND METHODS: Pharmacodynamic interactions were studied in scopolamine-induced cognitive impairment rats received two-weeks treatment of vehicle, EGb 761 and/or donepezil by the Morris water maze test and ex vivo evaluation of biomarkers of cholinergic transmission and oxidative stress in rat brain. In the meantime, pharmacokinetic profiles of donepezil and bilobalide were obtained and compared among all treatment groups. In addition, impact of the bioavailable EGb 761 components on donepezil brain penetration was evaluated with the hCMEC/D3 cell monolayer model. RESULTS: Scopolamine-induced rats with co-treatment of EGb 761 and donepezil had significantly improved cognitive function in the Morris water maze test with increased brain levels of superoxide dismutase and decreased brain levels of acetylcholinesterase and malondialdehyde than that with treatment of only EGb 761 or donepezil. Despite such beneficial pharmacodynamics outcomes, the two-week co-treatment of EGb 761 and donepezil did not alter the plasma pharmacokinetics and brain uptake of donepezil or bilobalide, which was further verified in the hCMEC/D3 monolayer model. CONCLUSION: Co-administration of EGb 761 and donepezil exerted better anti-amnestic effect via further enhanced pro-cholinergic and antioxidative effects of EGb 761 or donepezil in scopolamine-induced cognitive impairment rat without alteration in their systemic/brain exposure.


Subject(s)
Amnesia/drug therapy , Antioxidants/pharmacology , Cholinergic Agents/pharmacology , Donepezil/pharmacology , Nootropic Agents/pharmacology , Plant Extracts/pharmacology , Acetylcholinesterase/drug effects , Animals , Antioxidants/pharmacokinetics , Antioxidants/therapeutic use , Behavior, Animal/drug effects , Brain/drug effects , Brain/metabolism , Cell Line , Cholinergic Agents/blood , Cholinergic Agents/pharmacokinetics , Cholinergic Agents/therapeutic use , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/drug therapy , Cyclopentanes/blood , Cyclopentanes/pharmacokinetics , Cyclopentanes/pharmacology , Cyclopentanes/therapeutic use , Disease Models, Animal , Donepezil/blood , Donepezil/pharmacokinetics , Donepezil/therapeutic use , Drug Therapy, Combination , Furans/blood , Furans/pharmacokinetics , Furans/pharmacology , Furans/therapeutic use , Ginkgo biloba , Ginkgolides/blood , Ginkgolides/pharmacokinetics , Ginkgolides/pharmacology , Ginkgolides/therapeutic use , Humans , Male , Malondialdehyde/metabolism , Maze Learning/drug effects , Nootropic Agents/blood , Nootropic Agents/pharmacokinetics , Nootropic Agents/therapeutic use , Plant Extracts/blood , Plant Extracts/pharmacokinetics , Plant Extracts/therapeutic use , Rats, Wistar , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL